Asset Details
Do you wish to reserve the book?
The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)
Do you wish to request the book?
The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review)
2024
Overview
Lung cancer is currently the second most common type of cancer with the second incidence rate and the first mortality rate worldwide. Non-small cell lung cancer (NSCLC) accounts for ~85% of the total number of cases of lung cancers. Concerning the treatment of NSCLC, targeted therapy has become a research hotspot in recent years because of its favorable efficacy, high selectivity and minimal adverse reactions. Among the drugs used in targeted therapy, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the most common and are categorized into four generations. The use of first and second-generation drugs leads to drug resistance within 8-14 months. This resistance is primarily caused by the T790M mutation, which is the most observed mechanism. A third-generation drug has been developed to address this issue and a fourth-generation drug is expected to overcome multiple resistance mechanisms, including third-generation drug resistance. However, the fourth-generation drug has not been launched yet. At present, multiple third-generation targeted drugs have been launched globally, with three being launched in China and several being at research and clinical trial stages. The present article provides a review of the development process, mechanism of action and clinical trials of the third-generation EGFR-TKIs, aiming to provide some reference and suggestions for the clinical treatment of NSCLC and scientific research on third-generation targeted drugs.
Publisher
D.A. Spandidos,Spandidos Publications,Spandidos Publications UK Ltd
Subject
/ Cancer
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Complications and side effects
/ Drug Resistance, Neoplasm - genetics
/ epidermal growth factor receptor tyrosine kinase inhibitor
/ ErbB Receptors - antagonists & inhibitors
/ Humans
/ Kinases
/ Lung Neoplasms - drug therapy
/ Mutation
/ Protein Kinase Inhibitors - adverse effects
/ therapy
/ Tyrosine
